C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy
Blood Adv
.
2022 Dec 13;6(23):6071-6074.
doi: 10.1182/bloodadvances.2022008395.
Authors
Hridaya Shah
1
,
Hang Chen
2
3
,
Xiang-Zuo Pan
2
,
Ara Metjian
4
,
Robert A Brodsky
2
,
Evan M Braunstein
2
,
Shruti Chaturvedi
2
Affiliations
1
Zanvyl Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD.
2
Division of Hematology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD.
3
Committee on Genetics, Genomics and Systems Biology, Biological Sciences Division, University of Chicago, Chicago, IL.
4
Division of Hematology and Oncology, Department of Medicine, University of Colorado School of Medicine, Anschutz, CO.
PMID:
35914225
PMCID:
PMC9713277
DOI:
10.1182/bloodadvances.2022008395
No abstract available
Publication types
Research Support, N.I.H., Extramural
MeSH terms
Antineoplastic Agents* / adverse effects
Humans
Neoplasms* / complications
Neoplasms* / drug therapy
Thrombotic Microangiopathies* / chemically induced
Substances
Antineoplastic Agents
Grants and funding
K99 HL150594/HL/NHLBI NIH HHS/United States